MicroRNA-146a Inhibits Cancer Metastasis by Downregulating VEGF Through Dual Pathways in Hepatocellular Carcinoma
Overview
Oncology
Affiliations
Unlabelled: Growing evidence indicates that miR-146a is involved in carcinogenesis and tumor progression in several human malignancies. However, the molecular details underlying miR-146a mediated regulation of its target genes and its precise biological function in cancer, especially in hepatocellular carcinoma (HCC) remains unclear.
Methods: The expression levels of genes including miR-146a, APC, VEGF and HAb18G were examined in HCC cell lines and patient specimens were compared with control levels using quantitative reverse transcription-PCR. The functions of miR-146a and HAb18G in migration/invasion and liver metastasis formation were determined by transwell and spleen injection assays, respectively. miR-146a related genes were determined by PCR array. The potential regulatory targets of miR-146a were determined by bioinformatics and prediction tools, correlation with target protein expression, and luciferase reporter assay. DNA methylation status of miR-146a promoter were performed by PCR analysis of bisulfite-modified genomic DNA.
Results: We demonstrated that miR-146a expression was markedly downregulated in hepatoma cells and hepatoma tissues compared to immortalized normal liver epithelial cells and normal hepatic tissues. DNA methylation of miR-146a promoter correlated with its downexpression and with liver cancer metastasis. The restoration of miR-146a dramatically suppressed HCC cell invasion and metastasis by repressing VEGF expression through upregulating APC, which inhibits β-catenin accumulation in nucleus, and downregulating NF-κB p65 by targeting HAb18G. In human HCC, miR-146a expression was negative correlated with increased HAb18G, VEGF, NF-κB p65 and beneficial prognosis.
Conclusion: This study identified a novel target of miR-146a and defined miR-146a as a crucial tumor suppressor in human HCC that acts through multiple pathways and mechanisms to suppress HCC invasion or metastasis.
Sufianov A, Agaverdiev M, Mashkin A, Ilyasova T Noncoding RNA Res. 2025; 11():150-157.
PMID: 39829957 PMC: 11742574. DOI: 10.1016/j.ncrna.2024.12.002.
Nakano T, Goto S, Chen C Int J Mol Sci. 2024; 25(17).
PMID: 39273280 PMC: 11395488. DOI: 10.3390/ijms25179331.
Matboli M, Diab G, Saad M, Khaled A, Roushdy M, Ali M J Clin Exp Hepatol. 2024; 14(6):101456.
PMID: 39055616 PMC: 11268357. DOI: 10.1016/j.jceh.2024.101456.
Tofacitinib Regulates Endostatin via Effects on CD147 and Cathepsin S.
Zisman D, Sabtan H, Rahat M, Simanovich E, Haddad A, Gazitt T Int J Mol Sci. 2024; 25(13).
PMID: 39000375 PMC: 11241738. DOI: 10.3390/ijms25137267.
Inflammation and tumor microenvironment.
Niu T, Zhou F Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2024; 48(12):1899-1913.
PMID: 38448384 PMC: 10930746. DOI: 10.11817/j.issn.1672-7347.2023.230231.